drugset / Trial / NCT04970914
Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003
NaSingle-groupOpen-labelTreatment
Summary
A single-arm, open-label clinical trial, focus on the safety and efficacy of anlotinib hydrochloride in combination with Penpulimab (AK105) in patients with Chemo-refractory Metastatic Colorectal Cancer (mCRC)
Timeline
- Start
- 2021-11-05
- Primary completion
- 2022-08-23
- Completion
- 2023-08-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | Oral |
| Subject | Penpulimab | Monoclonal antibody | 200 mg | Intravenous |